Quest Diagnostics of the United States obtained urgent approval from the US Food and Drug Administration to use a new method to detect infection of the emerging corona virus, as the new method allows the analysis of patient samples in groups rather than one sample behind another, which allows a significant increase in the speed of analysis of samples.
The US Food and Drug Administration said it had reissued the Emergency Diagnostic Authorization for Quest Diagnostics to use its own analysis technique, Quest SARS-Covid-2R ARTI-PCR, to use a set of samples containing up to four samples obtained from During a swab for everyone under observation. The Quest method is the first multi-sample analysis method to detect emerging corona virus that is licensed for use.
It is mentioned that in multi-sample analysis, each person’s sample is obtained in a bottle of his own, but then laboratory technicians collect these samples in small groups for group analysis. In the event that the result of the analysis results in a negative set of samples, this means that all the sample owners are not infected with the virus. In the event that the result appears positive, each of the group’s samples will be analyzed individually to determine the positive and negative samples in them, according to Quest Diagnostics mentioned in a statement.
The company says this method is effective for assessing patients, areas, or population groups with low rates of disease. The group analysis method is frequently used in blood banks to detect the presence of viruses in the donated blood.
The technique is effective for populations with low incidence.
Follow our latest local and sports news and the latest political and economic developments via Google news